medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2024, Número 4

<< Anterior Siguiente >>

Acta Pediatr Mex 2024; 45 (4)


Guía de Práctica Clínica Mexicana para la Prevención de Infección por Virus Sincitial Respiratorio en Lactantes de Alto Riesgo

Moreno-Espinosa S, Robledo-Galván AE, Noyola-Cherpitel DE, Quiles-Corona M, Mayorga-Butrón JL, Aguilar-Gómez NE, Coronado-Zarco IA, García-Aguilar H, Soto-Ramos M, Martínez-Bustamante ME, Erdmenger-Orellana J, Villegas-Silva R, Ruiz-Gutiérrez HH, Macias-Avilés H, Rodríguez-Vega M

Idioma: Español
Referencias bibliográficas: 94
Paginas: 369-412
Archivo PDF: 638.65 Kb.


RESUMEN

La infección por VSR sigue siendo la primera causa de hospitalización por infección de vías aéreas inferiores en niños en nuestro país y a nivel global. Se calculan más de 3.6 millones de hospitalizaciones por esta causa en todo el mundo y más de 26,000 defunciones anualmente. La mayor incidencia de hospitalizaciones ocurre en lactantes menores de seis meses, y ciertos grupos son particularmente vulnerables, los cuales tienen un riesgo incrementado de hospitalizaciones y muerte asociadas a infección por VSR. Este grupo de pacientes, que será definido y tratado en este documento, es candidato a recibir estrategias de prevención que hayan demostrado disminuir el riesgo de un mal desenlace en salud.
ESTE documento constituye la Guía de Práctica Clínica (GPC) elaborada por iniciativa de la Academia Mexicana de Pediatría en colaboración con la Agencia Iberoamericana de Desarrollo y Evaluación de Tecnologías en Salud, con el objetivo de establecer recomendaciones basadas en la mejor evidencia disponible y consensuadas por un grupo interdisciplinario de expertos clínicos y metodológicos. Las meta este documento son brindar recomendaciones para disminuir el riesgo de infección por VSR tanto en la comunidad como en el ámbito hospitalario, principalmente en lactantes que tienen un riesgo incrementado de complicaciones y muerte. Este documento cumple con estándares internacionales de calidad, como los descritos por el Instituto de Medicina de Estados Unidos de América (EUA) (IOM, por sus siglas en inglés), el Instituto de Excelencia Clínica de Gran Bretaña (NICE, por sus siglas en inglés), la Red Colegiada para el Desarrollo de Guías de Escocia (SIGN, por sus siglas en inglés) y la Red Internacional de Guías de Práctica Clínica (G-I-N, por sus siglas en inglés). Se integró un Grupo de Desarrollo interdisciplinario de expertos clínicos y metodólogos con experiencia en revisiones sistemáticas de la literatura y el desarrollo de guías de práctica clínica. Se condujo un proceso de panel Delphi modificado para extraer la opinión de los expertos y lograr un nivel de consenso adecuado en cada una de las cinco recomendaciones clave contenidas en este documento.
Esperamos que este documento contribuya a apoyar la toma de decisiones de profesionales de la salud, elaboradores de políticas públicas, representantes de pacientes y sus cuidadores para lograr una mejor calidad en la atención y sobre todo disminuir la carga de la enfermedad por infección por VSR en este grupo vulnerable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Scotta MC, Stein RT. Current strategies and perspectivesfor active and passive immunization against RespiratorySyncytial Virus in childhood. J Pediatr (Rio J). marzo de 2023;99:S4-11.

  2. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA,Gessner BD, et al. Global, regional, and national diseaseburden estimates of acute lower respiratory infectionsdue to respiratory syncytial virus in young children in2015: a systematic review and modelling study. Lancet2017 Sep 2;390(10098):946-958 doi: 101016/S0140-6736(17)30938-8.

  3. Moreno-Espinosa S, Estrada-Ruelas I, Sánchez-MirandaY, Flores-Arizmendi RA, Macías-Avilés HA, Ruiz-GutiérrezHH, et al. Prevención de la infección grave por virussincicial respiratorio en la población pediátrica enMéxico: postura de un grupo de expertos. Bol Med HospInfant Mex 2020;77(3):100-111 English doi: 1024875/BMHIM19000166

  4. Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA,Zar HJ, et al. Risk factors for respiratory syncytial virus associatedwith acute lower respiratory infection in childrenunder five years: Systematic review and meta-analysis. JGlob Health. 2015;5(2).

  5. Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. MortalityAmong US Infants and Children Under 5 Years of Age withRespiratory Syncytial Virus and Bronchiolitis: A SystematicLiterature Review. Vol. 226, Journal of Infectious Diseases.Oxford University Press; 2022. p. S267–81.

  6. Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM,Losada JV, et al. Mortality due to respiratory syncytial virusburden and risk factors. Am J Respir Crit Care Med. el 1 deenero de 2017;195(1):96–103.

  7. Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM,Losada JV, et al. Mortality due to respiratory syncytial virusburden and risk factors. Am J Respir Crit Care Med. el 1 deenero de 2017;195(1):96–103.

  8. Rodriguez-Fernandez R, Mejias A, Ramilo O. MonoclonalAntibodies for Prevention of Respiratory Syncytial VirusInfection. Pediatric Infectious Disease Journal. el 26 demayo de 2021;40(5S):S35–9.

  9. Topalidou X, Kalergis AM, Papazisis G. Respiratory SyncytialVirus Vaccines: A Review of the Candidates and theApproved Vaccines. Vol. 12, Pathogens. MultidisciplinaryDigital Publishing Institute (MDPI); 2023.

  10. Verwey C, Madhi SA. Review and Update of Active andPassive Immunization Against Respiratory Syncytial Virus.BioDrugs. el 25 de mayo de 2023;37(3):295–309.

  11. Shi T, Vennard S, Mahdy S, Nair H. Risk Factors for PoorOutcome or Death in Young Children With RespiratorySyncytial Virus-Associated Acute Lower Respiratory TractInfection: A Systematic Review and Meta-Analysis. J InfectDis. el 12 de agosto de 2022;226(1):S10–6.

  12. Who strategy for global respiratory syncytial virus surveillanceproject based on the influenza platform [Internet].2019. http://apps.who.int/bookorders.

  13. Updated Guidance for Palivizumab Prophylaxis AmongInfants and Young Children at Increased Risk of Hospitalizationfor Respiratory Syncytial Virus Infection. http://publications.aap.org/pediatrics/article-pdf/134/2/e620/1103824/peds_2014-1666.pdf

  14. Canada. National Advisory Committee on Immunization,Public Health Agency of Canada. Recommended use ofpalivizumab to reduce complications of respiratory syncytialvirus infection in infants. 151 p.

  15. González-Ortiz AM, Bernal-Silva S, Comas-García A, Vega-Morúa M, Garrocho-Rangel ME, Noyola DE. Severe RespiratorySyncytial Virus Infection in Hospitalized Children. ArchMed Res. 2019;50(6):377–83.

  16. Hernández-Rivas L, Pedraz T, Calvo C, San Juan I, MelladoMa. J, Robustillo A. Respiratory syncytial virus outbreak duringthe COVID-19 pandemic. How has it changed? EnfermInfecc Microbiol Clin. 2022;

  17. Reicherz F, Yang Xu R, Abu-Raya B, Majdoubi A, GoldingL, Stojic A, et al. Waning immunity against respiratorysyncytial virus during the COVID-19 pandemic 1 2. https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

  18. Ramilo O, Rodriguez-Fernandez R, Mejias A. RespiratorySyncytial Virus Infection: Old Challenges and New Approaches.J Infect Dis [Internet]. el 30 de enero de 2023;Disponible en: https://academic.oup.com/jid/advancearticle/doi/10.1093/infdis/jiad010/7003275

  19. Duijts L, van Meel ER, Moschino L, Baraldi E, Barnhoorn M,Bramer WM, et al. European Respiratory Society guidelineon long-term management of children with bronchopulmonarydysplasia. European Respiratory Journal. el 1 deenero de 2020;55(1).

  20. Weigl JAI, Puppe W, Schmitt HJ. Incidence of RespiratorySyncytial Virus-Positive Hospitalizations in Germany. Vol.20, Eur J Clin Microbiol Infect Dis. Springer-Verlag; 2001.

  21. Updated Guidance for Palivizumab Prophylaxis AmongInfants and Young Children at Increased Risk of Hospitalizationfor Respiratory Syncytial Virus Infection. http://publications.aap.org/pediatrics/article-pdf/134/2/e620/1103824/peds_2014-1666.pdf

  22. Paes B, Fauroux B, Figueras-Aloy J, Bont L, Checchia PA,Simões EAF, et al. Defining the Risk and Associated Morbidityand Mortality of Severe Respiratory Syncytial Virus InfectionAmong Infants with Chronic Lung Disease. Vol. 5, InfectiousDiseases and Therapy. Springer Healthcare; 2016. p. 453–71.

  23. Joffe S, Escobar GJ, Black SB, Anne Armstrong M, Lieu TA.Rehospitalization for Respiratory Syncytial Virus AmongPremature Infants [Internet]. Disponible en: http://pediatrics.aappublications.org/

  24. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, CarrD, Belohradsky BH, et al. Incidence and risk factors ofrespiratory syncytial virus-related hospitalizations in prematureinfants in Germany. Eur J Pediatr. el 1 de abril de2003;162(4):230–6.

  25. Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, BurgessS, et al. Health care utilisation of infants with chroniclung disease, related to hospitalisation for RSV infection[Internet]. Vol. 85, Arch Dis Child. 2001. Disponible en:www.archdischild.com

  26. Groothuis JR, Fryzek JP, Makari D, Steffey D, MartoneWJ. Respiratory syncytial virus hospitalization trends ininfants with chronic lung disease of infancy, 1998-2008.Clin Epidemiol. el 29 de septiembre de 2011;3(1):245–50.

  27. Weigl JAI, Puppe W, Schmitt HJ. Incidence of RespiratorySyncytial Virus-Positive Hospitalizations in Germany. Vol.20, Eur J Clin Microbiol Infect Dis. Springer-Verlag; 2001.

  28. Checchia PA, Paes B, Bont L, Manzoni P, Simões EAF, FaurouxB, et al. Defining the Risk and Associated Morbidity and Mortalityof Severe Respiratory Syncytial Virus Infection AmongInfants with Congenital Heart Disease. Vol. 6, InfectiousDiseases and Therapy. Springer Healthcare; 2017. p. 37–56.

  29. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N,Kongstad T, et al. Risk factors for respiratory syncytial virushospitalisation in children with heart disease. Arch DisChild. octubre de 2009;94(10):785–9.

  30. Resch B, Kurath-Koller S, Hahn J, Raith W, KöstenbergerM, Gamillscheg A. Respiratory syncytial virus-associatedhospitalizations over three consecutive seasons in childrenwith congenital heart disease. European Journal of ClinicalMicrobiology and Infectious Diseases. el 1 de julio de2016;35(7):1165-9.

  31. Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D,Pérez-Yarza E, et al. Risk factors for hospitalization dueto respiratory syncytial virus infection among infants inthe Basque Country, Spain. Epidemiol Infect. junio de2006;134(3):506-13.

  32. Ák ZS, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T,et al. Predictors of RSV LRTI hospitalization in infants bornat 33 to 35 weeks gestational age: A large multinationalstudy (PONI). PLoS One. el 1 de junio de 2016;11(6).

  33. Feltes TF, Sondheimer HM, Tulloh RMR, Harris BS, JensenKM, Losonsky GA, et al. A Randomized Controlled Trial ofMotavizumab Versus Palivizumab for the Prophylaxis ofSerious Respiratory Syncytial Virus Disease in ChildrenWith Hemodynamically Significant Congenital Heart Disease[Internet]. Vol. 70, Pediatr Res. 2011. Disponible en:www.pedresearch.org

  34. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I,Chung WK, et al. Pediatric pulmonary hypertension. Vol.132, Circulation. Lippincott Williams and Wilkins; 2015.p. 2037–99.

  35. Thorburn K. Pre-existing disease is associated with a significantlyhigher risk of death in severe respiratory syncytial virusinfection. Arch Dis Child. febrero de 2009;94(2):99–103.

  36. Ratti C, Greca A della, Bertoncelli D, Rubini M, Tchana B.Prophylaxis protects infants with congenital heart diseasefrom severe forms of RSV infection: an Italian observationalretrospective study: Palivizumab prophylaxis in childrenwith congenital heart disease. Ital J Pediatr. el 1 de diciembrede 2023;49(1).

  37. Altman CA, Englund JA, Demmler G, Drescher KL, AlexanderMA, Watrin C, et al. Respiratory syncytial virus in patientswith congenital heart disease: A contemporary look at epidemiologyand success of preoperative screening. PediatrCardiol. 2000;21(5):433–8.

  38. Tulloh R, Flanders L, Henderson J, Thompson R, FeltesT. Does RSV infection cause pulmonary hypertension inchildren undergoing cardiac surgery? Arch Dis Child. el 1de abril de 2011;96(Supplement 1):A37–8.

  39. Stagliano DR, Nylund CM, Eide MB, Eberly MD. Childrenwith down syndrome are high-risk for severe respiratorysyncytial virus disease. Journal of Pediatrics. el 1 de marzode 2015;166(3):703-709.e2.

  40. Zachariah P, Ruttenber M, Simões EAF. Down syndromeand hospitalizations due to respiratory syncytial virus: Apopulation-based study. Journal of Pediatrics. 2012;160(5).

  41. Benítez-Guerra D, Piña-Flores C, Zamora-López M,Escalante-Padrón F, Lima-Rogel V, González-Ortiz AM, et al.Respiratory syncytial virus acute respiratory infectionassociatedhospitalizations in preterm Mexican infants: Acohort study. Influenza Other Respir Viruses. el 1 de marzode 2020;14(2):182–8.

  42. Moyes J, Cohen C, Pretorius M, Groome M, Von GottbergA, Wolter N, et al. Epidemiology of respiratory syncytialvirus-associated acute lower respiratory tract infectionhospitalizations among HIV-infected and HIV-uninfectedSouth African children, 2010-2011. Journal of InfectiousDiseases. el 12 de diciembre de 2013;208(SUPPL. 3).

  43. Greenberg D, Dagan R, Shany E, Bar-Ziv J, Givon-Lavi N.Increased risk for respiratory syncytial virus-associated,community-acquired alveolar pneumonia in infants bornat 31-36 weeks of gestation. Pediatric Infectious DiseaseJournal. 2014;33(4):381–6.

  44. Lu L, Yan Y, Yang B, Xiao Z, Feng X, Wang Y, et al. Epidemiologicaland clinical profiles of respiratory syncytial virusinfection in hospitalized neonates in Suzhou, China. BMCInfect Dis. el 15 de octubre de 2015;15(1).

  45. Okubo Y, Morisaki N, Michihata N, Matsui H, FushimiK, Yasunaga H. Dose-dependent relationships betweenweight status and clinical outcomes among infants hospitalizedwith respiratory syncytial virus infections. PediatrPulmonol. el 1 de abril de 2018;53(4):461–6.

  46. Tripathi S, Al-Sayyed B, Gladfelter TR. Comparative epidemiology,hospital course, and outcomes of viral respiratoryinfections in hospitalized pediatric patients. Indian J MedMicrobiol. el 1 de enero de 2021;39(1):24-9.

  47. Omer SB, Bednarczyk R, Kazi M, Beryl Guterman L, Aziz F,Allen KE, et al. Assessment and Validation of SyndromicCase Definitions for Respiratory Syncytial Virus Testing ina Low Resource Population. Pediatric Infectious DiseaseJournal. el 1 de marzo de 2019;38(3):E57–9.

  48. Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, BoomJA, et al. Respiratory Syncytial Virus-Associated HospitalizationsAmong Young Children: 2015-2016 [Internet].Disponible en: www.aappublications.org/news

  49. Hoover J, Eades S, Lam WM. Pediatric antiviral stewardship:Defining the potential role of ribavirin in respiratorySyncytial Virus-Associated lower respiratory Illness. Journalof Pediatric Pharmacology and Therapeutics. el 1 de septiembrede 2018;23(5):372-8.

  50. French CE, McKenzie BC, Coope C, Rajanaidu S, ParanthamanK, Pebody R, et al. Risk of nosocomial respiratorysyncytial virus infection and effectiveness of control measuresto prevent transmission events: a systematic review.Vol. 10, Influenza and other Respiratory Viruses. BlackwellPublishing Ltd; 2016. p. 268-90.

  51. Esparza-Miranda LA, Juárez-Tobías S, Muñoz-EscalanteJC, Oliva-Jara UA, Cadena-Mota S, Wong-Chew RM, et al.Clinical and Epidemiologic Characteristics of Infants Hospitalizedwith Respiratory Syncytial Virus Infection During the2022–2023 Season in Mexico. Pediatr Infect Dis J 2023 Oct1;42(10):e382-e384 doi: 101097/INF0000000000004013Epub 2023 Jun 22 PMID: 37345924.

  52. Jefferson T, Dooley L, Ferroni E, Al-Ansary LA, vanDriel ML, Bawazeer GA, et al. Physical interventions tointerrupt or reduce the spread of respiratory viruses.Cochrane Database Syst Rev 2023 Jan 30;1(1):CD006207doi: 101002/14651858CD006207.pub6 PMID: 36715243;PMCID: PMC9885521.

  53. Stanley Ip I, Leader Mei Chung P, Gowri Raman M, ChewP, Nombulelo Magula M, DeVine D, et al. Breastfeedingand Maternal and Infant Health Outcomes in DevelopedCountries: Evidence Report/Technology Assessment, No.153 [Internet]. 2007. Disponible en: www.ahrq.gov

  54. Dixon DL. The role of human milk immunomodulators inprotecting against viral bronchiolitis and development ofchronic wheezing illness. Vol. 2, Children. MDPI; 2015. p.289–304.

  55. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, KummelingI, et al. Factors influencing the composition of theintestinal microbiota in early infancy. Pediatrics. agostode 2006;118(2):511–21.

  56. Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, ChariRS, et al. Gut microbiota of healthy Canadian infants: Profilesby mode of delivery and infant diet at 4 months. CMAJCanadian Medical Association Journal. el 19 de marzo de2013;185(5):385–94.

  57. Lönnerdal B. Breast milk: a truly functional food. Nutrition2000 Jul-Aug;16(7-8):509-11 doi: 101016/s0899-9007(00)00363-4 PMID: 10906538.

  58. Tsutsumi H, Honjo T, Nagai K, Chiba Y, Chiba S, Tsugawa S.Immunoglobulin A antibody response to respiratory syncytialvirus structural proteins in colostrum and milk. J Clin Microbiol1989 Sep;27(9):1949-51 doi: 101128/jcm2791949-19511989 PMID: 2778061; PMCID: PMC267715.

  59. Toms GL, Gardner PS, Pullan CR, Scott M, Taylor C. Secretionof Respiratory Syncytial Virus Inhibitors and Antibodyin Human Milk Throughout Lactation. Vol. 5, Journal ofMedical Virology. 1980.

  60. Nishimura T, Suzue J, Kaji H. Breastfeeding reduces theseverity of respiratory syncytial virus infection amongyoung infants: A multi-center prospective study. PediatricsInternational. 2009;51(6):812–6.

  61. Cunningham AS, Jelliffe DB, Jelliffe EFP. MEDICAL PROGRESSBreast-feeding and health in the A global epidemiologicreview 980s. Vol. 118. 1991.

  62. Van Der Strate BWA, Beljaars L, Molema G, Harmsen MC,Meijer DKF. Antiviral activities of lactoferrin [Internet]. Vol.52, Antiviral Research. 2001. Disponible en: www.elsevier.com/locate/antiviral

  63. Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin andsurfactant protein A exhibit distinct binding specificity to Fprotein and differently modulate respiratory syncytial virusinfection. Eur J Immunol. octubre de 2003;33(10):2894-902.

  64. Mineva GM, Purtill H, Dunne CP, Philip RK. Impact ofbreastfeeding on the incidence and severity of respiratorysyncytial virus (RSV)-associated acute lower respiratoryinfections in infants: a systematic review highlighting theglobal relevance of primary prevention. BMJ Glob Health.el 6 de febrero de 2023;8(2).

  65. Jang MJ, Kim YJ, Hong S, Na J, Hwang JH, Shin SM, et al.Positive association of breastfeeding on respiratory syncytialvirus infection in hospitalized infants: A multicenterretrospective study. Clin Exp Pediatr. 2020;63(4):135-40.

  66. WHO Framework Convention on Tobacco Control, ShibuyaK, Ciecierski C, Guindon E, Bettcher DW, Evans DB, et al2003. WHO Framework Convention on Tobacco Control,Shibuya K, Ciecierski C, Guindon E, Bettcher DW, EvansDB, et al.

  67. Romero-Martínez M, María Téllez-Rojo Solís M, en DC,Andrea Sandoval-Zárate A, Manuel Zurita-Luna J, PabloGutiérrez-Reyes J. Análisis retrospectivo de la EncuestaNacional de Adicciones 2008. Identificación y correcciónde sesgo.

  68. Benowitz NL, Francisco S, Kuyt F, Jacob P, Jones RT, OsmanAL, et al. Cotinine is the major metabolite of nicotine9(Fig. 1). Cotinine is present in the blood of tobacco smokersin much higher concentrations Cotinine dispositionand effects.

  69. Gryczyn´ska D, Gryczyn´ska G, Kobos J, Zakrzewska A. Relationshipbetween passive smoking, recurrent respiratorytract infections and otitis media in children [Internet]. Vol.49, International Journal of Pediatric Otorhinolaryngology.1999. Disponible en: www.elsevier.com

  70. Marco Tejero A, Pérez Trullén A, Córdoba García R, GarcíaSánchez N, Cabañas Bravo MJ. La exposición al humode tabaco en el hogar aumenta la frecuentación porpatología respiratoria en la infancia. An Pediatr (Engl Ed).2007;66(5):475-80.

  71. Bermúdez Barrezueta L, Miñambres Rodríguez M, PalomaresCardador M, Torres Ballester I, López Casillas P,Moreno Carrasco J, et al. Effect of prenatal and postnatalexposure to tobacco in the development of acute bronchiolitisin the first two years of life. An Pediatr (Engl Ed). el 1de junio de 2021;94(6):385–95.

  72. Hwang SH, Hwang JH, Moon JS, Lee DH. Environmentaltobacco smoke and children’s health. Korean J Pediatr.2012;55(2):35–41.

  73. Jayes L, Haslam PL, Gratziou CG, Powell P, Britton J, VardavasC, et al. SmokeHaz: Systematic Reviews and Metaanalysesof the Effects of Smoking on Respiratory Health.En: Chest. Elsevier B.V.; 2016. p. 164–79.

  74. Stocks J, Dezateux C. The effect of parental smoking on lungfunction and development during infancy. Respirology 2003Sep;8(3):266-85 doi: 101046/j1440-1843200300478.x

  75. Maedel C, Kainz K, Frischer T, Reinweber M, ZacharasiewiczA. Increased severity of respiratory syncytial virus airwayinfection due to passive smoke exposure. Pediatr Pulmonol.el 1 de septiembre de 2018;53(9):1299–306.

  76. Difranza JR, Masaquel A, Barrett AM, Colosia AD, MahadeviaPJ. Systematic literature review assessing tobaccosmoke exposure as a risk factor for serious respiratorysyncytial virus disease among infants and young children[Internet]. 2012. Disponible en: http://www.biomedcentral.com/1471-2431/12/81

  77. Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, et al. Effects of parental and householdsmoking on the risk of respiratory syncytial virus (RSV)hospitalisation in late-preterm infants and the potentialimpact of RSV prophylaxis. Journal of Maternal-Fetal andNeonatal Medicine. junio de 2013;26(9):926–31.

  78. Bradley JP, Bacharier LB, Bonfiglio JA, Schechtman KB,Strunk R, Storch G, et al. Severity of respiratory syncytialvirus bronchiolitis is affected by cigarette smoke exposureand atopy. Pediatrics. enero de 2005;115(1).

  79. Semple MG, Taylor-Robinson DC, Lane S, Smyth RL.Household tobacco smoke and admission weight predictsevere bronchiolitis in infants independent of deprivation:Prospective cohort study. PLoS One. 2011;6(7).

  80. Faber T, Kumar A, Mackenbach JP, Millett C, Basu S, SheikhA, et al. Effect of tobacco control policies on perinatal andchild health: a systematic review and meta-analysis. LancetPublic Health. el 1 de septiembre de 2017;2(9):e420–37.

  81. Radó MK, Mölenberg FJM, Westenberg LEH, Sheikh A,Millett C, Burdorf A, et al. Effect of smoke-free policies inoutdoor areas and private places on children’s tobaccosmoke exposure and respiratory health: a systematicreview and meta-analysis. Lancet Public Health. el 1 deagosto de 2021;6(8):e566–78.

  82. Reproduced from the PATH website at www.path.org,[current date].

  83. Scotta MC, Stein RT. Current strategies and perspectivesfor active and passive immunization against RespiratorySyncytial Virus in childhood. J Pediatr (Rio J). noviembrede 2022;

  84. Brady MT, Byington CL, Davies HD, Edwards KM, JacksonMA, Maldonado YA, et al. Updated Guidance for PalivizumabProphylaxis Among Infants and Young Childrenat Increased Risk of Hospitalization for RespiratorySyncytial Virus Infection. Pediatrics. el 1 de agosto de2014;134(2):e620–38.

  85. Moore D, Sinilaite A, Killikelly A. Summary of the NationalAdvisory Committee on Immunization (NACI) statementupdate on the recommended use of palivizumab to reducecomplications of respiratory syncytial virus infection ininfants. Can Commun Dis Rep 2022 Jul 7;48(7-8):363-366doi: 1014745/ccdr.v48i78a08

  86. Reeves RM, van Wijhe M, Lehtonen T, Stona L, TeirlinckAC, Vazquez Fernandez L, et al. A Systematic Review ofEuropean Clinical Practice Guidelines for RespiratorySyncytial Virus Prophylaxis. J Infect Dis. el 12 de agosto de2022;226(Supplement_1):S110–6.

  87. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, EscobarLiquitay CM, Esteban I, Franco JV. Palivizumab for preventingsevere respiratory syncytial virus (RSV) infection inchildren. Cochrane Database of Systematic Reviews. el 16de noviembre de 2021;2021(11).

  88. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab forprophylaxis against respiratory syncytial virus infectionin children with cystic fibrosis. Cochrane Database ofSystematic Reviews.

  89. Kua KP, Lee SWH. Systematic Review of the Safety andEfficacy of Palivizumab among Infants and Young Childrenwith Cystic Fibrosis. Pharmacotherapy: The Journalof Human Pharmacology and Drug Therapy. junio de2017;37(6):755–69.

  90. Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Is palivizumab effective as a prophylaxis of respiratorysyncytial virus infections in cystic fibrosis patients?A meta-analysis. Allergol Immunopathol (Madr). mayo de2015;43(3):298–303.

  91. Gonzales T, Bergamasco A, Cristarella T, Goyer C, WojdylaM, Oladapo A, et al. Effectiveness and Safety of Palivizumabfor the Prevention of Serious Lower Respiratory Tract InfectionCaused by Respiratory Syncytial Virus: A SystematicReview. Am J Perinatol.

  92. Palivizumab, a Humanized Respiratory Syncytial VirusMonoclonal Antibody, Reduces Hospitalization FromRespiratory Syncytial Virus Infection in High-risk Infants.Pediatrics. el 1 de septiembre de 1998;102(3):531–7.

  93. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA,Top FH, et al. Palivizumab prophylaxis reduces hospitalizationdue to respiratory syncytial virus in young childrenwith hemodynamically significant congenital heart disease.Journal of Pediatrics. 2003;143(4):532–40.

  94. Tavsu I, Gursoy T, Dirman S, Erbil N, Ovali F. Palivizumabprophylaxis: Does it have any influence on the growthand development of the infants? Am J Perinatol.2014;31(8):667–72.




2020     |     www.medigraphic.com